NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT2071210037

Registered date:23/06/2021

A study in healthy Japanese men to test how well different doses of BI 1569912 are tolerated

Basic Information

Recruitment status Complete
Health condition(s) or Problem(s) studiedMajor Dipressive Disorder
Date of first enrollment21/07/2021
Target sample size44
Countries of recruitment
Study typeInterventional
Intervention(s)Drug: BI1569912 Other: Placebo

Outcome(s)

Primary Outcomethe percentage [%] of subjects with drug-related AEs per treatment group
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximum<= 45age old
GenderMale
Include criteriaHealthy male subjects according to the assessment of the investigator, as based on a complete medical history including a medical examination, vital signs (BP, PR), 12-lead ECG, and clinical laboratory tests Japanese ethnicity BMI of 18.5 to 25.0 kg/m2 (inclusive) Signed and dated written informed consent prior to admission to the study, in accordance with GCP and local legislation
Exclude criteriaAny finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 40 to 90 mmHg, or pulse rate outside the range of 40 to 99 bpm Any laboratory value outside the reference range that the investigator considers to be of clinical relevance Any evidence of a concomitant disease assessed as clinically relevant by the investigator Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair) Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders

Related Information

Contact

Public contact
Name Yoshifumi Tachibana
Address 2-1-1, Osaki, Shinagawa-ku, Toko Tokyo Japan 141-6017
Telephone +81-120-189-779
E-mail medchiken.jp@boehringer-ingelheim.com
Affiliation Boehringer Ingelheim
Scientific contact
Name Takumi Furuichi
Address 2-1-1, Osaki, Shinagawa-ku, Tokyo Tokyo Japan 141-6017
Telephone +81-120-189-779
E-mail medchiken.jp@boehringer-ingelheim.com
Affiliation Boehringer Ingelheim